VIA
RAPT

Vident Investment Advisory’s RAPT Therapeutics RAPT Stock Holding History

Vident Investment Advisory’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,924
Closed -$723K – 1316
2023
Q1 		$723K Sell
4,924
-180
-4% -$36.4K 0.02% 635
2022
Q4 		$808K Buy
+5,104
New +$817K 0.03% 542

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vident Investment Advisory's RAPT Position: Q2 2023 in Review

Vident Investment Advisory sold out of RAPT Therapeutics (RAPT) in Q2 2023, closing a stake of 4,924 shares — an estimated $723K sold.

Vident Investment Advisory first reported a position in RAPT in Q4 2022 and held it in 2 quarters. The position peaked at $808K in Q4 2022. 98 funds tracked by Wall St. Rank hold RAPT as of Q2 2023.

  • Vident Investment Advisory reported no remaining RAPT Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 4,924 RAPT Therapeutics shares in Q2 2023, an estimated $723K.
  • Vident Investment Advisory first reported a position in RAPT Therapeutics in Q4 2022 and held it in 2 quarters.
  • Vident Investment Advisory's RAPT Therapeutics position peaked at $808K in Q4 2022.
  • 98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.